Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoTSE:4527 -1.72%92 Piotroski F-Score is 4 as of Jul. 21, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates TSE:4527 with a GF Score™ of 92/100 and a GF Value™ of 円3,477.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,914 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks worse than 67.08% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Rohto Pharmaceutical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Rohto Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:
TSE:4527'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 8
Current: 4
During the past 13 years, the highest Piotroski F-Score of Rohto Pharmaceutical Co was 8. The lowest was 4. And the median was 5.
Rohto Pharmaceutical Co (TSE:4527) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Rohto Pharmaceutical Co Piotroski F-Score Related Terms
Rohto Pharmaceutical Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4527 vs PG, CL, KVUE: Piotroski F-Score Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Piotroski F-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Rohto Pharmaceutical Co's current Net Income (TTM) was 34,247.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Rohto Pharmaceutical Co's current Cash Flow from Operations (TTM) was 47,788.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Rohto Pharmaceutical Co's return on assets of this year was 0.07836143. Rohto Pharmaceutical Co's return on assets of last year was 0.08909078.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Rohto Pharmaceutical Co's gearing of this year was 0.07694325. Rohto Pharmaceutical Co's gearing of last year was 0.12863406.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Rohto Pharmaceutical Co's current ratio of this year was 2.03899479. Rohto Pharmaceutical Co's current ratio of last year was 2.30296592.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Rohto Pharmaceutical Co's number of shares in issue this year was 235.715. Rohto Pharmaceutical Co's number of shares in issue last year was 228.927.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Rohto Pharmaceutical Co's gross margin of this year was 0.56060804. Rohto Pharmaceutical Co's gross margin of last year was 0.5650644.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Rohto Pharmaceutical Co's asset turnover of this year was 0.78648587. Rohto Pharmaceutical Co's asset turnover of last year was 0.89152885.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
0
+
0
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Rohto Pharmaceutical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Rohto Pharmaceutical Co (TSE:4527) has a Piotroski F-Score of 4 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Rohto Pharmaceutical Co and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Rohto Pharmaceutical Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #1284 out of 1914 companies in the Consumer Packaged Goods industry, placing it in the top 67.1%.
Is Rohto Pharmaceutical Co's Piotroski F-Score too high?
Rohto Pharmaceutical Co's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. Rohto Pharmaceutical Co's value of 4 is 20% below this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #1284 out of 1914 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Piotroski F-Score compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #1284 out of 1914 companies for Piotroski F-Score. This places Rohto Pharmaceutical Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Rohto Pharmaceutical Co's value of 4 is 20% below this benchmark. Historically, Rohto Pharmaceutical Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Rohto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,914 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Significantly Undervalued. The stock's GF Value™ is 円3,477.35, compared to a current price of 円2,435.00 — trading 30% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Consumer Packaged Goods industry median of 5.00. Rohto Pharmaceutical Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current Piotroski F-Score is 4 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,435.00 is trading 30% below its estimated GF Value™ of 円3,477.35.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TSE:4527:
Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
GF Value™: 円3,477.35 vs. price of 円2,435.00 (30% below fair value)
Industry Position: 20% below the Consumer Packaged Goods median (#1284 of 1914)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
92GF Score
Get the complete analysis for TSE:4527
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
